Entering text into the input field will update the search result below

180 Life Sciences Continues Uptrend With Cannabinoid And Anti-Inflammatory Research

Apr. 07, 2021 1:56 AM ET180 Life Sciences Corp. (ATNF)39 Comments
Alan Sumler profile picture
Alan Sumler


  • 180 Life Sciences, a clinical stage research company, went public last November.
  • The company brings together six scientists famous for their work in anti-inflammatory research.
  • They have several projects underway, one of which uses cannabinoids to treat arthritis and chronic pain.
  • The company has proceeds from Direct Offerings and Private Placement.
  • The company’s stock price has increased 182% in 3 months and should be watched for a potential 43% profit.

180 Life Sciences (NASDAQ:ATNF) merged with KBL Merger Corp. IV and went public last November. The company brings together six famous medical researchers/doctors who have proven track records in anti-inflammatory treatments, running clinical studies, and bringing drugs to market. The co-founders of the company paved the way for ant-inflammatory drugs like Remicade and Humira, which are used to treat Crohn’s Disease and other chronic illnesses.

The company has potential for both value and growth. Their research shows promise and the market for anti-inflammatory drugs are growing. Their business strategy is twofold: to find new applications for existing anti-inflammatory drugs and to find new anti-inflammatory drug candidates like cannabinoids. The company has low operating costs because most of their research is paid for by grants. Their stock price has been on an uptrend at 182% in three months. There is no revenue or future revenue, so the investor must consider their research and business potential.

The company specializes in the application of anti-TNF (tumor necrosis factor) antibodies, which treat autoimmune inflammatory diseases like rheumatoid arthritis, ulcerative colitis, and Crohn’s disease. These are all conditions where the body’s immune system causes harm to the body. The company believes that other diseases may be treated with anti-inflammatory antibodies. The drug market for anti-TNF drugs makes up about $40 billion per year and the co-founders of the company pioneered this market through their research and business dealings.

The company goes public with four pre-clinical studies and three clinical stage studies. They have a grant-funded Phase 2b/3 clinical trial that applies anti-ATNF drugs to early stages of Dupuytrens’ contracture, a fibrotic disease of the hand. They expect results from the study by the end of Q4-2021. Currently, there is no known early treatment for the condition. The company is presenting the first treatment using an already existing anti-ATNF

This article was written by

Alan Sumler profile picture
Welcome to the home of The Cannabis Report: a monthly report on the cannabis industry. I am an analyst and consultant in the cannabis industry. I have contributed to High Times Magazine. I currently have a book out, Cannabis in the Ancient Greek and Roman World. I am most interested in technical stock analysis, option strategies, small cap strategies, and emerging markets. Feel free to contact me with any questions about the cannabis industry or publicly traded stocks in the cannabis industry.

Analyst’s Disclosure: I am/we are long ATNF. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.